Key result
Plasma concentrations of human Urotensin II were comparable between patients with chronic heart failure and control subjects at rest (2990 vs 3290 pg/ml, n.s.) and at peak exercise.
Why the study?
Are circulating plasma levels of human Urotensin II (hU-II) altered in patients with chronic heart failure compared to controls at rest and during exercise?
Case-Control (n=42)
Are circulating plasma levels of human Urotensin II (hU-II) altered in patients with chronic heart failure compared to controls at rest and during exercise?
Absolute Event Rate: 2990% vs 3290%
p-value: p=n.s.
Circulating plasma levels of human Urotensin II do not differ between patients with chronic heart failure and controls at rest or during exercise, suggesting it may not be a useful circulating biomarker for CHF.
hU-II levels are similar in CHF and controls at rest and exercise; leaves open its utility as a circulating biomarker.
BACKGROUND: Human Urotensin II (hU-II) is the most potent vasoconstrictor known to date. HU-II receptors are predominant in the human heart and arterial vessels, suggesting hU-II to be of importance as a cardiovascular mediator. METHODS: We studied 32 consecutive patients (60+/-12 years) with chronic heart failure (CHF) and 10 control subjects (54+/-12 years, n.s.) with cardiopulmonary exercise testing. Blood samples for the measurement of plasma hU-II and big-endothelin-1 (big-ET1) were obtained at rest and at peak exercise. RESULTS: Peak VO(2) was significantly higher in controls than in CHF patients (19.8+/-3.8 vs. 14.7+/-3.6 ml min(-1) kg(-1), P<0.001). Big-ET1 levels were increased in CHF compared to controls at rest (2.8+/-1.8 vs. 1.7+/-0.1 fmol/ml, P<0.01) and at peak exercise (2.7+/-1.7 vs. 1.6+/-0.2 fmol/ml, P<0.005). HU-II concentrations were comparable in patients with CHF and controls at rest (2990+/-1104 vs. 3290+/-508 pg/ml, n.s.) and peak exercise (3063+/-1185 vs. 3213+/-1188 pg/ml, n.s.). Resting hU-II levels demonstrated no correlation with peak VO(2) in controls or CHF patients. CONCLUSIONS: The measurement of circulating plasma levels of hU-II does not seem to be very helpful in studying the effects of hU-II in human cardiovascular regulation. A local paracrine or autocrine mediator effect of hU-II in CHF is possible.
No takes yet. Share an insight, caveat, or question.
Krüger et al. (2004) conducted a case-control in Chronic heart failure (n=42). Chronic heart failure vs. Control subjects was evaluated on Plasma hU-II concentrations at rest (pg/ml) (p=n.s.). Plasma concentrations of human Urotensin II were comparable between patients with chronic heart failure and control subjects at rest (2990 vs 3290 pg/ml, n.s.) and at peak exercise.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: